Clinical study of Tianma Gouteng Granules combined with Madopar in the treatment of Parkinson disease
WANG Zheng1 LAI Tianbao2 WANG Xiaoxi3 LI Xiaofeng4
1.Department of Neurology, Hangzhou Seventh People′s Hospital, Zhejiang Province, Hangzhou 310007, China;
2.Department of Neurology, Zhongshan Hospital Affiliated to Xiamen University, Fujian Province, Xiamen 361004, China;
3.Department of Pathology, the First Affiliated Hospital of Zhejiang University Medical School, Zhejiang Province, Hangzhou 310000, China;
4.Department of Neurology, Guangxi Zhuang Autonomous Region People′s Hospital, Guangxi Zhuang Autonomous Region, Nanning 530021, China
Abstract:Objective To study the clinical efficacy of Tianma Gouteng Granules combined with Madopar in the treatment of Parkinson disease (PD). Methods From April 2016 to February 2018, 174 patients with PD admitted in Hangzhou Seventh People′s Hospital were selected. According to the random number table method, the patients were divided into observation group and control group, 87 cases in each group. The control group was treated with Madopar and the observation group was treated with Tianma Gouteng Granules on the basis of the control group. The two groups were treated for 3 months, 3 months was 1 course of treatment. The efficacy, inflammatory index, oxidative stress index, unified parkinson disease rating scale (UPDRS), mini mental state examination (MMSE) and medication safety were compared. Results The total effective rate of the observation group was 96.55%, which was significantly higher than 88.51% of the control group, the difference was statistically significant (P < 0.05). After 3 months of treatment, the level of nterleukin-4 and superoxide dismutase in both groups was higher than that before treatment, and the level in the observation group was higher than that in the control group, tumor necrosis factor-α and malonaldehyde level in the two groups was lower than before treatment, and the observation group was lower than the control group, the differences were statistically significant(all P < 0.05). After 3 months of treatment, the MMSE score of the two groups was significantly higher than that before treatment, and the observation group was higher than that of the control group, the UPDRS scores of the two groups were significantly lower than those before treatment, and the observation group was lower than that of the control group, the differences were statistically significant (all P < 0.05). The total incidence of adverse reactions in the observation group was 6.90%, compared with 9.20% of the control group, the difference was not statistically significant (P > 0.05). Conclusion Tianma Gouteng Granules combined with Madopar is effective in the treatment of PD. It can effectively improve the inflammatory state and oxidative stress level of patients, and improve their cognitive function. The drug is safe and worthy of promotion.
王郑1 赖天宝2 王小西3 李晓峰4. 天麻钩藤颗粒联合美多芭治疗帕金森病的临床研究[J]. 中国医药导报, 2019, 16(2): 63-66,71.
WANG Zheng1 LAI Tianbao2 WANG Xiaoxi3 LI Xiaofeng4. Clinical study of Tianma Gouteng Granules combined with Madopar in the treatment of Parkinson disease. 中国医药导报, 2019, 16(2): 63-66,71.